encourag favor setup result srra revers split
common stock ratio revers split expect compli
list requir think current trade level may
attract addit investor would previous reluct restrict
invest stock trade updat model reduc share
count adjust pt maintain outperform rate
srra appear well track view execut pivot
momentum trial compar studi momelotinib vs danazol symptomatic/
anem myelofibrosi mf patient previous treat jak inhibitor patient
enrol on-going addit site post ct gov us hungari
israel
one key invest point clinic hypothes srra
momelotinib inhibitor allevi anemia symptom
via inhibit interestingli recent investor updat
manag also hypothes also known inhibit
decreas hepcidin level allevi anemia think might provid
addit valid srra right track
previous mention possibl proven anemia benefit
momelotinib may lead synergist combin trial agent
indic luspatercept bet inhibitor potenti collabor
remind standard care first-lin mf treatment ruxolitinib
signific ex-u sale believ potenti second-lin mf treatment
momelotinib may face compar ex-u commerci opportun approv
ema srra own world-wide right momelotinib leav door
open possibl ex-u out-licens partner
think srra on-going momentum clinic execut effort well
indirect valid possibl role mf opportun reinforc
invest thesi base sale estim momelotinib turn
support outperform rate srra pt
year price histori srra
clinic
therapeut treatment
patient cancer engag
busi research develop
commerci therapi
treatment patient cancer
found may sierra
headquart vancouv canada
analyst certif import disclosur see disclosur
outperform rate srra base belief
share under-valued base evalu
compani main asset momelotinib registr
clinic trial myelofibrosi patient previous treat jak
inhibitor think current mf patient primarili
administ ruxolitinib first-lin eventu discontinu
current treatment due sever factor includ diseas
progress new second-lin option
need address mf symptom believ momelotinib
well posit secur treatment given uniqu chemic
structur prior clinic trial publish literatur
activ momelotinib demonstr registr momentum
period updat momentum trial
updat retrospect analysi simplifi studi
updat momentum trial enrollment/progress
addit data analys eha
top-line data momelotinib
posit differenti momelotinib activ momentum
novel momelotinib trial cancer indic
financ greater
advanc pipelin asset
acquisit signific premium
expect
momelotinib activ momentum trial disappoint result
momentum clinic trial take longer expect and/or
show statist signific
competit landscap mf limit momelotinib commerci
post-reverse-split price target srra base dcf valuat methodolog assum wacc
residu growth rate anticip launch momelotinib peak sale patent expir
forecast ww risk-adjust momelotinib sale driven momelotinib mf indic probabl success
momelotinib mf indic mf anemia indic
key downsid risk price target clinic develop regulatori risk momelotinib addit risk includ build
commerci infrastructur target indic higher anticip competit mf agent above-averag stock-pric
volatil owe stock microcap statu limit float upsid risk includ acquisit signific premium better
expect clinic data momelotinib
momelotinib mf
probabl success
momelotinib mf risk-adjust
momelotinib mf anemia
probabl success
momelotinib mf anemia risk-adjust
good
royalti
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex sg
